Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Further improvements of ide-cel therapy in KarMMa trials

Larry Anderson • 4 Jun 2021
ASCO 2021
Multiple Myeloma Idecabtagene vicleucel

Larry Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX, suggests improvements for ide-cel therapy in the KarMMa trials. Dr. Anderson recommends starting the treatment earlier in the course of therapy when T-cells are possibly more functional. There is not any data as of yet on this recommendation, so results still need to come out but there is hope for earlier intervention being more impactful. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Larry Anderson

0:52
Inequality in access to CAR-T therapy in multiple myeloma and the importance of addressing this
Larry Anderson • 28 Sep 2023
2:58
The impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel
Larry Anderson • 28 Sep 2023
5:16
Updated KarMMa results: ide-cel in R/R myeloma
Larry Anderson • 4 Jun 2021

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals